Mannkind Corporation (NASDAQ:MNKD) has entered a co-promotion agreement with Vertice Pharma for Thyquidity oral solution (levothyroxine sodium) through MannKind’s specialty sales team.
MannKind to co-promote Thyquidity
Thyquidity is a replacement therapy in thyroidal, pituitary, and hypothalamic acquired or congenital hypothyroidism. However, the levothyroxine sodium solution has not been indicated for benign thyroid nodules and nontoxic diffuse goiter suppression in iodine-sufficient individuals or hypothyroidism during a subacute thyroiditis recovery phase.
According to the agreement terms, MannKind’s sales team will promote Thyquidity to pediatric endocrinologists, adult endocrinologists as well as other healthcare providers in the US treating hypothyroidism. On the other hand, Vertice will pay MannKind quarterly to defray additional promotional activity costs. MannKind will be subject to sales royalties on returns from Thyquidity sales.
Michael Castagna, MannKind’s CEO said that they are delighted to sign the agreement to co-promote Thyquidity. He added that the arrangement will allow the company to enhance its relationship with its current customers and expansion into pediatric endocrinology. It will also help MannKind leverage the capabilities and talent of its sales force as well as their reimbursement support.
Thyquidity to launch in Q1 2021
Vertice Pharma’s CEO Scott Meyers said that the company is excited to collaborate with MannKind to help in the launch of Thyquidity to healthcare providers and patients. He added that they are looking forward to working with MannKind’s sales force for the launch of the product in the first quarter of 2021.
Hypothyroidism is often referred to as underactive thyroid disease which is a common disorder that affects the thyroid gland making it not to produce adequate thyroid hormone. In the US hypothyroidism preference is around 4.6% and symptoms range from cold intolerance, fatigue, lethargy, constipation, weight gain, dry skin, and change in voice. In most cases, patients require lifelong therapy to manage hypothyroidism.
Vertice’s Thyquidity has been indicated as replacement therapy for acquired or congenital hypothyroidism. However, it has not been indicated for benign thyroid nodules or nontoxic diffuse goiter suppression since there are no clinical benefits. Also, over-treatment with Thyquidity could induce hyperthyroidism.